Clinical Trials
The Department of Radiation Oncology enrolls as many as 200 new patients each year in clinical trials. Faculty members hold leadership positions in the Radiation Therapy Oncology Group (RTOG), which develops and oversees all national radiation oncology trials funded by the National Cancer Institute.
See current clinical trial information below or contact the Clinical Research office at 214-645-7322.
Breast
Therapeutic
STU 052018.052 (GammaPod Boost) Tumor Bed Boost Using a Breast-Specific Radiosurgery Device, the GammaPod: Registry Study and Evaluation of Quality of Life with Development of Sizing Nomogram. Learn about the GammaPod.
STU 2018.0236 (Tailor RT) A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node-Positive Breast Cancer.
STU 2024.0561 (RAPS) Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer.
Central Nervous System
Therapeutic
STU 122016.064 (Neurocog Decline) Phase I/II Trial to Determine the Neurocognitive Decline in Patients with Multiple (>6) Brain Metastases Treated with Distributed Stereotactic Radiosurgery.
Gastrointestinal
Therapeutic
STU 2020.1394 (Rectal PULSAR) Phase I Trial of Ultra-Fractionated Adaptive Radiotherapy, Chemotherapy and Selective Omission of Surgery for Locally Advanced Rectal Cancer.
STU 2024-0601 (ULTRAS) Ultra-High-Dose Radiation for Liver Metastasis Using MR-Guided Treatment with Stereotactic Ablative Single-Fraction (ULTRAS): Phase III Randomized Controlled Trial.
STU 2024.0475 (Morpheus) A Phase III Study Testing Two Dose Escalation Strategies to Increase the Population of Complete Responders After Radiation Therapy in the Context of Organ Preservation for Patients With Rectal Cancer.
Genitourinary
Therapeutic
STU 2021.08760 (NRG-GU010) Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE).
STU 2023.0566 (PULSAR ProPhet) Phase 1B Study of Personalized Ultrahypofractionated Stereotactic Ablative Radiotherapy of High-Risk PROstate Cancer Guided by PET PSMA (68Ga PMSA-11; Ilucix) Response.
STU 2024.0024 A Study of a Non-Significant Risk (NSR) Device: [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on the RefleXion X1 System in Patients Already Undergoing Diagnostic PET PSMA Imaging.
STU 2024.0919 (SPARK) STING Agonist and Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy in Combination with Checkpoint Inhibition for Patients with Metastatic Kidney Cancer.
STU 2024.U0755 (HYDROSPACE) SpaceIT Hydrogel System for Perirectal Spacing in Subjects with Low to Intermediate Risk Prostate Cancer Undergoing External Beam Radiotherapy (EBRT).
STU 2019.06838 (NRG-GU008) Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE).
STU 2025-1220 (RANGER) Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy.
Gynecological
Therapeutic
STU 2021.0852 Daily Adaptive External Beam Radiation Therapy in the Treatment of Carcinoma of the Cervix: A Phase II Trial of an Individualized Approach for Intestinal Toxicity Reduction (ARTIA-Cervix).
Head and Neck
Therapeutic
STU 2023.0715 (G-FORCE) Phase II Randomized Study of Glottic Larynx Hypofractionated Radiotherapy Versus Conventional Radiotherapy.
STU 2024.0603 (INVERT) Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy.
STU 2024.0171 (KEVLARx) A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx.
Lung
Therapeutic
STU 022015.069 (JoLT-Ca/STABLEMATES) A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC), the STABLEMATES Trial. Learn more about the JoLT-CA/STABLEMATES trial.
STU 2024.1215 Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung.